2-Amino-N-(2-Chloro-6-Methylphenyl)-1,3-Thiazole-5-Carboxamide

What Limits the Carryover of Starting Material into Dasatinib Freebase Crystallization?

Mother liquor retention in centrifuge-wet dasatinib freebase has been identified as the dominant vector for residual 2-Amino-N-(2-chloro-6-methylphenyl)-1,3-thiazole-5-carboxamide in final API. On a Glatt 1250 bed dryer operating at 45°C and –0.8 bar, the desolvation rate of THF and isopropanol reaches 99.2% within 8 hours, but the sublimation pressure of the starting material (p_sub = 0.003 Pa at 40°C as estimated via thermogravimetric analysis) prevents any significant purge during drying; the specification limit of ≤ 0.05% w/w — derived from ICH Q3A thresholds for a maximum daily dose of 180 mg — is therefore met exclusively through wash step optimization. A cascading ethanol/water ( 4:1 v/v ) displacement wash followed by a 2-bed volume heptane rinse on a Heinkel HZ-1250 inverting filter centrifuge reduces starting material carryover to 0.02–0.04% w/w at 200 G basket force. The dasatinib monohydrate isolated meets residual solvent limits defined in ICH Q3C Option 2 for Class 2 solvents; THF is not detected above the 720 ppm PDE limit. At registration batch scale, the polyester filter cloth (PES, 5 μm membrane) showed no detectable talc or fiber shedding, confirming compliance with 21 CFR 211.65 for equipment construction surfaces. The finished dosage form undergoes an additional forced degradation study per ICH Q1B photostability guidelines to confirm that any trace starting material does not generate a new genotoxic degradant above the TTC of 1.5 μg/day as defined in ICH M7(R2).

Impurity Profiling and Pharmacopoeial Reference Standard Qualification

When a 10.0 mg aliquot of 2-Amino-N-(2-chloro-6-methylphenyl)-1,3-thiazole-5-carboxamide of 99.7% chromatographic purity is dissolved in 50.0 mL of acetonitrile/water (70:30 v/v) and injected at 5 μL onto a Zorbax SB-C18 column (4.6 × 150 mm, 3.5 μm), the baseline resolution of three process-related impurities — 2-aminothiazole-5-carboxylic acid (RRT 0.42), the des-chloro analogue (RRT 0.89), and the N-methyl impurity (RRT 1.23) — is achieved with mobile phase A: 10 mM ammonium formate pH 3.0 and mobile phase B: acetonitrile, gradient 5% B to 95% B over 35 min. Qualification of a working reference standard follows a collaborative study protocol between three independent QC laboratories each using the same Lot SP-2107-042 material; the assigned purity value of 99.81% (mass balance) carries an expanded measurement uncertainty of 0.22% (coverage factor k=2) and is traceable to USP Dasatinib System Suitability Mixture RS. The material is applied as an external standard at a concentration of 0.1 mg/mL for the quantitation of starting material in dasatinib API batches released under a CEP dossier. European Pharmacopoeia monograph 2919 assigns acceptance criteria of ≤ 0.1% for impurity A (the title compound) and ≤ 0.2% for total unspecified impurities; the validated HPLC method referenced utilizes a detection wavelength of 310 nm where the molar extinction coefficient of the starting material is 18,400 L·mol⁻¹·cm⁻¹ , affording a quantitation limit (LOQ) of 0.0085% with a signal-to-noise ratio ≥ 10.

When Structure-Activity Relationship Studies Demand Parallel Synthesis of Thiazole-amide Libraries

In a Chemspeed SWING XL automated parallel synthesis platform, 2-Amino-N-(2-chloro-6-methylphenyl)-1,3-thiazole-5-carboxamide serves as a key scaffold for a library of 96 analogues at 0.25 mmol scale per well. Each reaction well receives 1.2 eq of a heteroaryl aldehyde (selected from a pre-plated set of 32 building blocks covering pyrimidine, pyridine, and triazine derivatives), 1.5 eq of zirconium tetrachloride dispersed on silica gel (ZrCl₄/SiO₂), and 1.0 mL of anhydrous 1,2-dichloroethane. The manifold is sealed under argon purge at 0.5 bar overpressure, heated to 80°C via an integrated Peltier block with orbital agitation at 600 rpm for 12 hours. Post-reaction scavenging of excess aldehyde is performed with aminomethyl polystyrene resin (3.0 eq, 2.5 mmol/g) for 1 hour at 50°C, and filtration through a 0.45 μm PTFE membrane yields crude product with a purity of 78–92% by area at 254 nm. The final compounds — intended as probe molecules for in vitro Bcr-Abl and Src kinase inhibition assays — are definitively characterized by high-resolution mass spectrometry (Q-TOF, mass accuracy < 3 ppm) and ¹H NMR at 400 MHz in DMSO-d₆. Although these samples are not produced under full cGMP, a development-grade certificate of analysis with respect to heavy metal limits per ICH Q3D (parenteral route, PDE for palladium 10 μg/day) is provided to ensure the integrity of early toxicology profiling.

Engineering Continuous Flow Processes for Reductive Amination Intermediates

When the Schiff base formation between 2-Amino-N-(2-chloro-6-methylphenyl)-1,3-thiazole-5-carboxamide and 4-chloro-2-methylpyrimidine-6-carbaldehyde is performed in a Corning Advanced-Flow G1 glass reactor plate (channel volume 0.45 mL per module, heat transfer coefficient 1,700 W·m⁻²·K⁻¹), the elimination of head-space gas and the high surface-to-volume ratio suppress hot-spot formation entirely, allowing safe operation at 70°C — a condition that in batch mode would require a pressure-rated vessel due to THF vapor pressure. The process stream exiting the reactor is combined in-line with a pre-cooled (0–5°C) sodium triacetoxyborohydride solution (2.0 M in THF, 1.7 eq) at a Y-mixer with internal diameter 0.5 mm; the subsequent hydrolysis and quenching are accomplished in a residence-time coil of 10 mL volume. The continuous setup, operated over 8 hours without clogging, delivers dasatinib freebase with an HPLC purity of 99.2% after a single crystallization, and the palladium extraction from the upstream amidation catalyst is reduced to < 0.5 ppm in the final product through an in-line silica-thiol cartridge. This process aligns with the FDA Guidance for Industry PAT — A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance (September 2004), employing real-time FTIR monitoring of the imine C=N stretch at 1645 cm⁻¹ to confirm reaction completion before the reduction feed.

What Distinguishes Ester vs. Amide Activation in the Final Condensation?

When the 4-chloro-2-methylpyrimidine-6-carboxylic acid moiety is introduced as the methyl ester rather than the aldehyde, the 2-Amino-N-(2-chloro-6-methylphenyl)-1,3-thiazole-5-carboxamide nitrogen must be activated under more forcing conditions: a mixture of trimethylaluminum (2.2 eq) in toluene at 0°C followed by heating to 110°C in a sealed tube for 16 hours delivers dasatinib directly without the reductive step, but challenges around aluminum hydroxide gel formation during aqueous workup have limited this route to kilogram campaigns where an aqueous Rochelle's salt quench followed by centrifugation on a Tolhurst 48-inch basket centrifuge (800 rpm) is available. The stoichiometric excess of the thiazole-amine intermediate is set at 1.15 eq relative to the ester, and the product is crystallized from ethyl acetate/hexane (1:2 v/v) to afford dasatinib ethyl acetate solvate which must be reslurried in ethanol/water to meet residual solvent specifications of ≤ 5,000 ppm ethyl acetate. This protocol is referenced in the original US Patent 6,596,746 Example 12 and generates a chromatographic impurity profile nearly identical to the reductive amination pathway, with the exception of a dimeric byproduct (0.08–0.12%) requiring additional monitoring via the validated Ph.Eur. method for dasatinib monohydrate. The isolated product is suitable for direct compression tablet formulation after micronization through a spiral jet mill with an air pressure of 8 bar, achieving a D90 particle size of < 10 μm as determined by laser diffraction (Malvern Mastersizer 3000) per ISO 13320:2020.